Komori
Kringle Pharma (4884) · PolicyFirst stated

Contributing to the Resolution of Social Issues and Sustainability Through the Core Business

First written in FY2023. . Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Addressing ESG Issues through Business Activities and Promoting WomenA theme 8 companies write about · 0 as a headwind · 9 as a tailwind

The whole theme swung hardest in 2024: 1 of 6 companies on the "Worse" side.

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023First statedAnnual report

    「Under our corporate philosophy of conducting research and development on treatments for intractable diseases, providing patients suffering from serious diseases with innovative treatment options, and contributing to society, we have worked through our core business of pharmaceutical research and development to resolve social issues and contribute to the development of industry and society.」

    The company states that, from a sustainability perspective, it contributes to resolving social issues and developing industry and society through pharmaceutical research and development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kringle Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.